CLAIMS

1. A maleate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.

2. The salt of claim 1, wherein the salt is crystalline.

3. The salt of claim 1, wherein the salt is a crystalline anhydrous salt.

4. The salt of any one of claims 1-3, wherein the salt has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 6.0 ± 0.2, 20.3 ± 0.2, and 21.7 ± 0.2, wherein said powder X-ray diffraction pattern is obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

5. The salt of any one of claims 1-4, wherein the salt is a substantially pure polymorph of maleate polymorph Form A.

6. The salt of any one of claims 1-3, wherein the salt has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2, wherein said powder X-ray diffraction pattern is obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

7. The salt of any one of claims 1-3 and 6, wherein the salt has a solid state NMR spectrum comprising one or more ^{13}C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm.

8. The salt of any one of claims 1-3 and 6-7, wherein the salt has a solid state NMR spectrum comprising a ^{19}F chemical shift at -123.1 ppm ± 0.2.

9. The salt of any one of claims 1-3 and 6-8, wherein the salt has a powder X-ray diffraction pattern comprising: one or more or two or more or three peaks at diffraction angles (2θ) selected from the group consisting of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2 obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406

Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three ^{13}C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm; and a solid state NMR spectrum comprising a ^{19}F chemical shift at -123.1 ± 0.2 ppm.

10. The salt of any one of claims 1-3 and 6-9, wherein the salt is a substantially pure polymorph of maleate polymorph Form B.

11. A pharmaceutical composition comprising the salt of any of claims 1-10.

12. Use of a therapeutically effective amount of the pharmaceutical composition of claim 11 for the manufacture of a medicament for the treatment of a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity.

13. Use of a therapeutically effective amount of the pharmaceutical composition of claim 11 for the manufacture of a medicament for the treatment of cancer.

14. Use of a salt of any one of claims 1-10 in the manufacture of a medicament for the treatment of cancer.

CLAIMS

1. A maleate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.

2. The salt of claim 1, wherein the salt is crystalline.

3. The salt of claim 1, wherein the salt is a crystalline anhydrous salt.

4. The salt of any one of claims 1-3, wherein the salt is a polymorph of maleate polymorph Form A, wherein the salt has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 6.0 ± 0.2, 20.3 ± 0.2, and 21.7 ± 0.2, wherein said powder X-ray diffraction pattern is obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

5. The salt of any one of claims 1-3, wherein the salt has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2, wherein said powder X-ray diffraction pattern is obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

6. The salt of any one of claims 1-3 and 5, wherein the salt has a solid state NMR spectrum comprising one or more ^{13}C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm.

7. The salt of any one of claims 1-3 and 5-6, wherein the salt has a solid state NMR spectrum comprising a ^{19}F chemical shift at -123.1 ppm ± 0.2.

8. The salt of any one of claims 1-3 and 5-7, wherein the salt has a powder X-ray diffraction pattern comprising: one or more or two or more or three peaks at diffraction angles (2θ) selected from the group consisting of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2

obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three ^{13}C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm; and a solid state NMR spectrum comprising a ^{19}F chemical shift at -123.1 ± 0.2 ppm.

9. The salt of any one of claims 1-3 and 5-8, wherein the salt is a polymorph of maleate polymorph Form B, wherein the salt has a powder X-ray diffraction pattern comprising: one or more or two or more or three peaks at diffraction angles (2θ) selected from the group consisting of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2 obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

10. A pharmaceutical composition comprising the salt of any of claims 1-3 and 4-9.

11. Use of a therapeutically effective amount of the pharmaceutical composition of claim 11 for the manufacture of a medicament for the treatment of cancer.

12. Use of a salt of any one of claims 1-9 in the manufacture of a medicament for the treatment of cancer.